Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR27320688

—

9b5758e8-7eb7-5eb7-9ff6-47c72a6fce0c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
age_years
50.41666667

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
  • G2M_CHECKPOINT+0.450
  • E2F_TARGETS+0.440
  • WNT_BETA_CATENIN_SIGNALING+0.410
  • ESTROGEN_RESPONSE_EARLY+0.360
  • APICAL_JUNCTION+0.350
  • MTORC1_SIGNALING+0.350
  • NOTCH_SIGNALING+0.350
  • UV_RESPONSE_DN+0.340
  • MITOTIC_SPINDLE+0.330

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.360
  • PROTEIN_SECRETION-0.270
  • OXIDATIVE_PHOSPHORYLATION-0.180
  • INTERFERON_GAMMA_RESPONSE-0.150
  • DNA_REPAIR-0.110
  • HEME_METABOLISM-0.070
  • PEROXISOME-0.030
  • SPERMATOGENESIS-0.020
  • FATTY_ACID_METABOLISM+0.000
  • XENOBIOTIC_METABOLISM+0.020

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-A7-A6VV-01A-22R-A33J-07
breast-umap@18
—E0.820
2SRR2771207
melanoma-umap@29
——0.816
3TCGA-85-8353-01A-21R-2296-07
lung-landscapes@6
—cohortSQ10.807
4EPT0578
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.806
5TCGA-A1-A0SN-01A-11R-A144-07
breast-umap@18
—C0.804
6TCGA-C8-A135-01A-11R-A115-07
breast-umap@18
—C0.793
7C3N-01892
lung-landscapes@6
—cohortSQ10.787
8MDT-AP-0435
medullo-epn-umap@date-based
MedMedulloblastoma0.784
9ULC1427T_S35
lung-landscapes@6
—cohortSQ20.782
106ACB4FA8-1E5E-40FF-8C1F-980CF41215FB
brain-umap@2
——0.777

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 41 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.520Inavolisib— uncovered
G2M_CHECKPOINT0.450Inavolisib— uncovered
E2F_TARGETS0.440Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.410Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.360Inavolisib— uncovered
APICAL_JUNCTION0.350Inavolisib— uncovered
MTORC1_SIGNALING0.350Inavolisib— uncovered
NOTCH_SIGNALING0.350Inavolisib— uncovered
UV_RESPONSE_DN0.340Inavolisib— uncovered
MITOTIC_SPINDLE0.330Inavolisib— uncovered
MYC_TARGETS_V20.330Idelalisib— uncovered
PANCREAS_BETA_CELLS0.330Cobimetinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.320Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.310Inavolisib— uncovered
MYOGENESIS0.310Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.310Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.300Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.300Inavolisib— uncovered
KRAS_SIGNALING_UP0.290Inavolisib— uncovered
TGF_BETA_SIGNALING0.290Inavolisib— uncovered